Abstract
Esophageal cancer is one of the most difficult malignancies to cure, and identification of novel prognostic markers for patients with this disease is important. CD24 is a small highly glycosylated mucin-like protein. Several studies have shown that higher CD24 expression is significantly associated with shorter patient survival in various malignant tumors. However, the expression of CD24 and its clinicopathological significance in esophageal cancer remain largely unknown. Immunohistochemical analyses of CD24 and Ki-67 overexpression in 151 cases of esophageal squamous cell carcinoma were performed to examine the relationships of CD24 expression with clinicopathological parameters and patient survival. Five cell lines derived from esophageal cancer were subjected to Western blot analyses to evaluate CD24 expression. Immunohistochemically, CD24 expression was judged to be positive in 61 (40.4%) cases. CD24 expression was associated with lymph node metastasis (p = 0.005), pathologic stage (p = 0.018), number of nodal metastases (p = 0.003), lymphatic invasion (p = 0.002), venous invasion (p < 0.001), and Ki-67 labeling index (p < 0.001). The Pearson’s correlation coefficient between the CD24 expression score and the Ki-67 labeling index was 0.404 (p < 0.001). CD24 expression was associated with disease-free survival (p < 0.001). A Cox multivariate regression analysis revealed that CD24 expression was an independent prognostic factor (p = 0.033). On Western blot analysis, CD24 was detected in all five cell lines. We conclude that overexpression of CD24, which was correlated with Ki-67 expression, is a novel independent prognostic marker for identifying patients with poor prognosis after curative resection of esophageal squamous cell carcinoma.
Similar content being viewed by others
References
Kato H, Fukuchi M, Miyazaki T, et al. Surgical treatment for esophageal cancer. Current issues. Dig Surg. 2007;24:88–95.
Kuwano H, Masuda N, Kato H, Sugimachi K. The subepithelial extension of esophageal carcinoma for determining the resection margin during esophagectomy: a serial histopathologic investigation. Surgery. 2002;131:S14–21.
Iizuka T, Isono K, Kakegawa T, Watanabe H. Parameter linked to 10-year survival in Japan of resected esophageal carcinoma. Chest. 1989;96:1005–11.
Ohtsu A, Boku N, Muro K, et al. Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol. 1999;17:2915–21.
Ide H, Nakamura T, Hayashi K, Endo T, Kobayashi A, Eguchi R, et al. Esophageal squamous cell carcinoma: pathology and prognosis. World J Surg. 1994;18:321–30.
Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M. Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann Surg. 2000;232:225–32.
Kristiansen G, Sammar M, Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol. 2004;35:255–62.
Baumann P, Cremers N, Kroese F, et al. CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res. 2005;65:10783–93.
Suzuki T, Kiyokawa N, Taguchi T, Sekino T, Katagiri YU, Fujimoto J. CD24 induces apoptosis in human B cells via the glycolipid-enriched membrane domains/rafts-mediated signaling system. J Immunol. 2001;166:5567–77.
Kadmon G, von Bohlen und Halbach F, Schachner M, Altevogt P. Differential, LFA-1-sensitive effects of antibodies to nectadrin, the heat-stable antigen, on B lymphoblast aggregation and signal transduction. Biochem Biophys Res Commun. 1994;198:1209–15.
Sammar M, Gulbins E, Hilbert K, Lang F, Altevogt P. Mouse CD24 as a signaling molecule for integrin-mediated cell binding: functional and physical association with src-kinases. Biochem Biophys Res Commun. 1997;234:330–4.
Kadmon G, Eckert M, Sammar M, Schachner M, Altevogt P. Nectadrin, the heat-stable antigen, is a cell adhesion molecule. J Cell Biol. 1992;118:1245–58.
Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P. The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. Cancer Res. 2000;60:6714–22.
Kristiansen G, Winzer KJ, Mayordomo E, et al. CD24 expression is a new prognostic marker in breast cancer. Clin Cancer Res. 2003;9:4906–13.
Kristiansen G, Pilarsky C, Pervan J, et al. CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer. Prostate. 2004;58:183–92.
Zarn JA, Zimmermann SM, Pass MK, Waibel R, Stahel RA. Association of CD24 with the kinase c-fgr in a small cell lung cancer cell line and with the kinase lyn in an erythroleukemia cell line. Biochem Biophys Res Commun. 1996;225:384–91.
Welsh JB, Zarrinkar PP, Sapinoso LM, et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc Natl Acad Sci USA. 2001;98:1176–81.
Senner V, Sturm A, Baur I, Schrell UH, Distel L, Paulus W. CD24 promotes invasion of glioma cells in vivo. J Neuropathol Exp Neurol. 1999;58:795–802.
Huang LR, Hsu HC. Cloning and expression of CD24 gene in human hepatocellular carcinoma: a potential early tumor marker gene correlates with p53 mutation and tumor differentiation. Cancer Res. 1995;55:4717–21.
Sagiv E, Kazanov D, Arber N. CD24 plays an important role in the carcinogenesis process of the pancreas. Biomed Pharmacother. 2006;60:280–4.
Sagiv E, Lorenzo M, Karin A, et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology. 2006;131:630–9.
Kristiansen G, Schluns K, Yongwei Y, Denkert C, Dietel M, Petersen I. CD24 is an independent prognostic marker of survival in non-small cell lung cancer patients. Br J Cancer. 2003;88:231–6.
Aigner S, Sthoeger ZM, Fogel M, et al. CD24, a mucin-type glycoprotein, is a ligand for P-selectin on human tumor cells. Blood. 1997;89:3385–95.
Youssef EM, Matsuda T, Takada N, et al. Prognostic significance of the MIB-1 proliferation index for patients with squamous cell carcinoma of the esophagus. Cancer. 1995;76:358–66.
Nishihira T, Hashimoto Y, Katayama M, Mori S, Kuroki T. Molecular and cellular features of esophageal cancer cells. J Cancer Res Clin Oncol. 1993;119:441–9.
Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T and T.Tn) established from the oral tumor. Jpn J Oral Maxillofac Surg. 1990;36:307–16.
Miyazaki T, Kato H, Nakajima M, et al. FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma. Br J Cancer. 2003;89:140–5.
Barnas C, Martel-Planche G, Furukawa Y, Hollstein M, Montesano R, Hainaut P. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer. 1997;71:79–87.
Itoshima T, Fujiwara T, Waku T, et al. Induction of apoptosis in human esophageal cancer cells by sequential transfer of the wild-type p53 and E2F-1 genes: involvement of p53 accumulation via ARF-mediated MDM2 down-regulation. Clin Cancer Res. 2000;6:2851–9.
Akimoto T, Nonaka T, Ishikawa H, Sakurai H, Saitoh JI, Takahashi T, et al. Genistein, a tyrosine kinase inhibitor, enhanced radiosensitivity in human esophageal cancer cell lines in vitro: possible involvement of inhibition of survival signal transduction pathways. Int J Radiat Oncol Biol Phys. 2001;50:195–201.
Poncet C, Frances V, Gristina R, Scheiner C, Pellissier JF, Figarella-Branger D. CD24, a glycosylphosphatidylinositol-anchored molecules is transiently expressed during the development of human central nervous system and is a marker of human neural cell lineage tumors. Acta Neuropathol. 1996;91:400–8.
Cram DS, McIntosh A, Oxbrow L, Johnston AM, DeAizpurua HJ. Differential mRNA display analysis of two related but functionally distinct rat insulinoma (RIN) cell lines: identification of CD24 and its expression in the developing pancreas. Differentiation. 1999;64:237–46.
Shirasawa T, Akashi T, Sakamoto K, Takahashi H, Maruyama N, Hirokawa K. Gene expression of CD24 core peptide molecule in developing brain and developing non-neural tissues. Dev Dyn. 1993;198:1–13.
Figarella-Branger D, Moreau H, Pellissier JF, Bianco N, Rougon G. CD24, a signal-transducing molecule expressed on human B lymphocytes, is a marker for human regenerating muscle. Acta Neuropathol. 1993;86:275–84.
Redondo P, García-Foncillas J, Okroujnov I, de Felipe I, Quintanilla E. CD24 expression on human keratinocytes. Exp Dermatol. 1998;7:175–8.
Taguchi T, Kiyokawa N, Mimori K, et al. Pre-B cell antigen receptor-mediated signal inhibits CD24-induced apoptosis in human pre-B cells. J Immunol. 2003;170:252–60.
Sammar M, Aigner S, Altevogt P. Heat-stable antigen (mouse CD24) in the brain: dual but distinct interaction with P-selectin and L1. Biochim Biophys Acta. 1997;1337:287–94.
Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, et al. CD24 mediates rolling of breast carcinoma cells on P-selectin. FASEB J. 1998;12:1241–51.
Smith SC, Oxford G, Wu Z, et al. The metastasis-associated gene CD24 is regulated by Ral GTPase and is a mediator of cell proliferation and survival in human cancer. Cancer Res. 2006;66:1917–22.
Choi YL, Kim SH, Shin YK, Hong YC, Lee SJ, Kang SY, et al. Cytoplasmic CD24 expression in advanced ovarian serous borderline tumors. Gynecol Oncol. 2005;97:379–86.
Weichert W, Denkert C, Burkhardt M, et al. Cytoplasmic CD24 expression in colorectal cancer independently correlates with shortened patient survival. Clin Cancer Res. 2005;11:6574–81.
Chou YY, Jeng YM, Lee TT, et al. Cytoplasmic CD24 expression is a novel prognostic factor in diffuse-type gastric adenocarcinoma. Ann Surg Oncol. 2007;14:2748–58.
Lim SC, Oh SH. The role of CD24 in various human epithelial neoplasias. Pathol Res Pract. 2005;201:479–86.
Kruger JA, Kaplan CD, Luo Y, Zhou H, Markowitz D, Xiang R, et al. Characterization of stem cell-like cancer cells in immune-competent mice. Blood. 2006;108:3906–12.
Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells: an integrated concept of malignant tumor progression. Nat Rev Cancer. 2005;5:744–9.
Lam KY, Law SY, So MK, Fok M, Ma LT, Wong J. Prognostic implication of proliferative markers MIB-1 and PC10 in esophageal squamous cell carcinoma. Cancer. 1996;77:7–13.
Fischer A, Blanche S, Le Bidois J, et al. Anti-B-cell monoclonal antibodies in the treatment of severe B-cell lymphoproliferative syndrome following bone marrow and organ transplantation. N Engl J Med. 1991;324:1451–6.
Sagiv E, Starr A, Rozovski U, Khosravi R, Altevogt P, Wang T, et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res. 2008;68:2803–12.
Acknowledgements
The authors would like to thank Dr. T. Nishihira (Tohoku University, Japan) for kindly providing the TE cell lines, Dr. K. Takahashi (Chiba University, Japan) for providing the TTn cell line, and Mr. T. Hikino, Mrs. M. Saito, and Mr. F. Hara (Department of Diagnostic Pathology, Gunma University Graduate School of Medicine, Japan) for their excellent technical assistance.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sano, A., Kato, H., Sakurai, S. et al. CD24 Expression Is a Novel Prognostic Factor in Esophageal Squamous Cell Carcinoma. Ann Surg Oncol 16, 506–514 (2009). https://doi.org/10.1245/s10434-008-0252-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-008-0252-0